Inovio Pharma (INO) Misses Q3 EPS by 89c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Inovio Pharmaceuticals (INO) PT Lowered to $6 at RBC Capital
November 15, 2024 6:33 AM ESTRBC Capital analyst Gregory Renza lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $6.00 (from $7.00) while maintaining a Sector Perform rating.
The analyst comments "INOs 3Q print affirms INO-3107 in RRP as the companys primary focus during a time... More
